+41 91 682 20 40 info@elixi-int.com

Warning: getimagesize(/home/elixitom/public_html/wp-content/uploads/2016/10/logo_expopharm.jpg): failed to open stream: No such file or directory in /home/clients/5f0b4deb973bf941571734948687755e/web/elixi/wp-content/themes/Total/framework/classes/image-resize.php on line 116
ELIXI In Expopharm 2016

ELIXI in Expopharm 2016

The expopharm is the largest pharmaceutical trade fair in Europe: Many key decision-makers from all sectors of the industry anywhere else  would here. The current major manufacturers present their latest innovations in the industry, the leading software companies present the…

Read More

Warning: getimagesize(/home/elixitom/public_html/wp-content/uploads/2016/10/zykadia.jpg): failed to open stream: No such file or directory in /home/clients/5f0b4deb973bf941571734948687755e/web/elixi/wp-content/themes/Total/framework/classes/image-resize.php on line 116
Novartis ALK+ Metastatic NSCLC Therapy Zykadia® Extends Progression-free Survival Beyond 18 Months In Phase II Study

Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study

Progression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in ALKi-naïve patients with brain metastases at baseline, per blinded independent review committee…

Read More

Warning: getimagesize(/home/elixitom/public_html/wp-content/uploads/2016/10/IMG_4089.jpg): failed to open stream: No such file or directory in /home/clients/5f0b4deb973bf941571734948687755e/web/elixi/wp-content/themes/Total/framework/classes/image-resize.php on line 116
Pfizer Receives Positive CHMP Opinion For IBRANCE – Metastatic Breast Cancer In Europe

Pfizer Receives Positive CHMP Opinion For IBRANCE – Metastatic Breast Cancer In Europe

Pfizer Inc. (NYSE:PFE) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that IBRANCE® (palbociclib) be granted marketing authorization in the European Union (EU) for the…

Read More

Warning: getimagesize(/home/elixitom/public_html/wp-content/uploads/2016/09/dda9809a6cb21a22caabcea6dbd46a96.jpg): failed to open stream: No such file or directory in /home/clients/5f0b4deb973bf941571734948687755e/web/elixi/wp-content/themes/Total/framework/classes/image-resize.php on line 116
SOLIRIS (eculizumab) – Alexion

SOLIRIS (eculizumab) – Alexion

Soliris is a pharma product indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.   Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening disease of the blood characterized by destruction of red blood cells by…

Read More

Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)

NEW HAVEN, Conn.--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced topline results from the REGAIN study, a Phase 3 registration trial of eculizumab (Soliris®) in patients with refractory generalized myasthenia gravis (gMG). Refractory gMG is an ultra-rare segment of MG—a debilitating,…

Read More

Warning: getimagesize(/home/elixitom/public_html/wp-content/uploads/2016/07/ht_150203_ibrance_75mg_800x600.jpg): failed to open stream: No such file or directory in /home/clients/5f0b4deb973bf941571734948687755e/web/elixi/wp-content/themes/Total/framework/classes/image-resize.php on line 116
IBRANCE® (palbociclib) – Metastatic Breast Cancer

IBRANCE® (palbociclib) – Metastatic Breast Cancer

IBRANCE is a prescription medicine used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic) in combination with: letrozole as the first hormonal based therapy…

Read More

Warning: getimagesize(/home/elixitom/public_html/wp-content/uploads/2016/04/law-1063249.jpg): failed to open stream: No such file or directory in /home/clients/5f0b4deb973bf941571734948687755e/web/elixi/wp-content/themes/Total/framework/classes/image-resize.php on line 116
WDL

WDL

ELIXI International SA is a fully licensed pharmaceutical wholesaler: the license issued by the MOH (Swissmedic) includes vaccines, blood products and controlled drugs.    

Read More

Warning: getimagesize(/home/elixitom/public_html/wp-content/uploads/2016/04/laptop-1209008_1280.jpg): failed to open stream: No such file or directory in /home/clients/5f0b4deb973bf941571734948687755e/web/elixi/wp-content/themes/Total/framework/classes/image-resize.php on line 116
New Website!

New Website!

We are pleased to show you our new website, we will soon post information on the newest products released on the market and any info which might be interesting to our valued partners! Please stay tuned!

Read More

Warning: getimagesize(/home/elixitom/public_html/wp-content/uploads/2016/01/venclexta-logo-22-HR.jpg): failed to open stream: No such file or directory in /home/clients/5f0b4deb973bf941571734948687755e/web/elixi/wp-content/themes/Total/framework/classes/image-resize.php on line 116
FDA Approval: Venclexta

FDA Approval: Venclexta

The U. S. Food and Drug Administration approved venetoclax (VENCLEXTA tablets, marketed by AbbVie, Inc. and Genentech USA, Inc.) for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA-approved test, who have…

Read More